IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Immune Response to Seasonal Influenza Vaccine in HIV Infected Individuals
This study has been completed.
Sponsor:
George Washington University
Information provided by (Responsible Party):
George Washington University
ClinicalTrials.gov Identifier:
NCT01381029
First received: June 23, 2011
Last updated: February 8, 2016
Last verified: January 2016
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Investigators in the Division of Infectious Diseases are carrying out a study to determine if human immunodeficiency virus (HIV)-seropositive patients receiving the Seasonal Influenza vaccination develop an adequate antibody response. The study group will consist of individuals seen in the Infectious Diseases Clinic who are HIV-seropositive and receive the Seasonal Influenza vaccine.
| Condition |
|---|
| Influenza, Human Human Immunodeficiency Virus I Infection |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | A Study to Examine Immunological Response in HIV-Infected Patients Receiving the Seasonal Influenza Vaccine |
Resource links provided by NLM:
Further study details as provided by George Washington University:
Primary Outcome Measures:
- Change in antibody levels [ Time Frame: Pre-, 3 weeks post-, 3 months post- vaccine ]The primary endpoint will be to measure the change from baseline in vaccine-strain specific antibody levels. Titers of > or = 40 U will be considered protective and a > 4-fold rise in antibody titer will be considered an adequate response in previously antibody-negative patients. Data from this study will assist in defining the efficacy of the influenza vaccine in the HIV-infected population and the ability of HIV-infected patients to generate an appropriate immune response, as well as maintain an appropriate response, to the influenza vaccine.
| Enrollment: | 74 |
| Study Start Date: | September 2009 |
| Study Completion Date: | August 2014 |
| Primary Completion Date: | August 2014 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
HIV positive
HIV positive, receiving Influenza vaccine as standard of care.
|
Detailed Description:
This is a study to establish the immunologic response in HIV-seropositive individuals to the FDA approved seasonal influenza vaccine when it is available. HIV-seropositive individuals seen in the Infectious Diseases Clinic at George Washington University, Medical Faculty Associates and receive this vaccination, on label, as part of standard of care will be invited to participate.
The study will require a 10-ml sample of whole blood to be drawn from each participant prior to the dose of the seasonal influenza vaccine and at 3 weeks after the vaccine dose and at 3 months after the vaccine dose. No additional samples are envisioned. Serum will be separated and will frozen and stored in the Clinical Trials Unit until all patient samples have been obtained. At that time the antibody levels to the vaccine antigens will be measured.
Data that will be collected from the subject's medical record includes the following:
- Age, gender, race
- CD4 count
- HIV viral load
- History of prior influenza immunization including the 2009-2010 trivalent vaccine
- HIV antiviral medication history
Data that will be collected from the subject during participation in study
- Antibody levels prior to vaccination
- Dose date of the seasonal influenza vaccination
- Antibody levels 3 weeks after the vaccination
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
HIV positive individuals receiving influenza vaccine as part of standard of care.
Criteria
Inclusion Criteria:
- Males or female patients ages 18 or older
- Diagnosis of HIV infection
- No contraindications to being able to receive influenza vaccine by the treating physician
- No acute active illness
- Able to provide informed consent
Exclusion Criteria:
- Previous history of hypersensitivity reaction to influenza vaccine
- Unable to return for follow-up blood draw
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01381029
Please refer to this study by its ClinicalTrials.gov identifier: NCT01381029
Locations
| United States, District of Columbia | |
| Medical Faculty Associates | |
| Washington, District of Columbia, United States, 20037 | |
Sponsors and Collaborators
George Washington University
Investigators
| Principal Investigator: | Marc Siegel, MD | George Washington University |
More Information
| Responsible Party: | George Washington University |
| ClinicalTrials.gov Identifier: | NCT01381029 History of Changes |
| Other Study ID Numbers: |
IRB080911 |
| Study First Received: | June 23, 2011 |
| Last Updated: | February 8, 2016 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
Additional relevant MeSH terms:
|
Influenza, Human Immunologic Deficiency Syndromes Acquired Immunodeficiency Syndrome HIV Infections Orthomyxoviridae Infections RNA Virus Infections Virus Diseases Respiratory Tract Infections Respiratory Tract Diseases |
Immune System Diseases Lentivirus Infections Retroviridae Infections Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Slow Virus Diseases Vaccines Immunologic Factors Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on August 23, 2017